Highlights Redwood Pharma AB

Equities

REDW

SE0021512134

Delayed Nasdaq Stockholm Other stock markets 01:30:42 17/06/2024 pm IST			5-day change	1st Jan Change
1.96 ^SEK	+4.26%		+188.24%	-58.30%

08/05	Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	CI
07/05	Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Redwood Pharma AB's Product RP501 attracted a lot of interest at ARVO in Seattle	08/05	CI
Two International Companies Begin Due Diligence on Redwood Pharma AB's Product RP501 Ahead of Potential Commercial Agreements	07/05	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23/11	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07	CI
Redwood Pharma AB Presents Positive Results from Clinical Study with RP501 Against Dry Eye	01/23/01	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Redwood Pharma AB Completes Recruitment for Clinical Trial with RP501 for Dry Eye	17/23/17	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	15/23/15	CI
Redwood Pharma AB Completes Further Preparations for the Scale-Up of Production of the Company's Medical Technology Product RP501	24/23/24	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/22/31	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	31/22/31	CI
Redwood Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	10/22/10	CI
Redwood Pharma AB Announces First Patient Has Started Redwood Pharma's Rp501 Treatment for Dry Eye	05/22/05	CI
Redwood Pharma Receives Approval from Austrian Federal Office for Safety in Health Care to Initiate Clinical Trial of RP501	28/22/28	CI
Redwood Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	16/22/16	CI
Redwood Pharma Receives Approval from an Austrian Ethics Committee for Start of A Clinical Trial of RP501	07/22/07	CI
Redwood Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	16/21/16	CI
Redwood Pharma AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	27/21/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Redwood Pharma AB

Equities

REDW

SE0021512134

Highlights

Filters